| Returns | 1W : 3.2% , 1M : 15.2%,1Y : -3.1% |
| Peers & Returns | 1W | 1M | 1Y |
| HESTER BIOSCIENCES | 3.2% | 15.2% | -3.1% |
| SUN PHARMACEUTICAL INDUSTRIES | -7.2% | -7.5% | 20.6% |
| DRREDDYS LABORATORIES | -0.5% | 15.2% | 84% |
| DIVIS LABORATORIES | -3.1% | -6.4% | 91.1% |
| CIPLA | 0.3% | 1.9% | 62.4% |
| PIRAMAL ENTERPRISES | -2.2% | -18.2% | -35.4% |
| LUPIN | -4.1% | 1.5% | 32.1% |
| AUROBINDO PHARMA | -2.4% | -11.9% | 22.6% |
| TORRENT PHARMACEUTICALS | 0.6% | -1.1% | 55.7% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S PEG |
35.08 8.59 8.99 - |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
127% 70% 71% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For Banking industry, Good = Ratio less than 13 Average = Ratio between 13 and 15 Bad = Ratio greater than 15 For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0.24 0.21 0.29 0.25 |
0.6 0.51 0.49 0.53 |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As of : July 14,2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Parameter | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
-6.17% 30.05% 60.15% 52.42% |
-8.37% -24.62% -28.96% -22.18% |
| QtrlyTrend |
-2
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Jun2020 | ||
